Loxapac

Quick links to important sections

Loxapac

Method of action: Psychoanaleptics, Psycholeptics

Treatment option: Bronchospasm, Schizophrenia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loxapac

Property Description
Active ingredient Loxapine
Pharmacological class First-Generation Antipsychotic (Typical Neuroleptic)
Chemical structure Dibenzoxazepine derivative (Tricyclic)
Dosage forms Capsules, Oral concentrate, Solution for injection
Route of administration Oral, Intramuscular (IM)
Origin Synthetic compound

Definition and Pharmacological Classification

Loxapac is a prescription-only medication whose active ingredient, Loxapine, is clinically recognized as a first-generation antipsychotic (FGA), an agent often referred to as a typical neuroleptic. Loxapine is a synthetic compound derived from the Dibenzoxazepine chemical structure. This identity as an FGA distinguishes it from newer agents and confirms its established role in managing significant central nervous system disturbances.

Active Component and Available Forms

Loxapac is manufactured as a single-ingredient product, containing only the therapeutic substance Loxapine. The medication is provided in several distinct dosage forms for flexibility: capsules and an oral concentrate for ingestion via the oral route, as well as a sterile solution for injection intended for intramuscular (IM) administration. This range of forms is a key feature, allowing for both sustained oral therapy and the rapid intervention offered by the IM route, consistent with its primary use in managing both chronic and acute presentations of severe mental health conditions.

General Purpose of the Antipsychotic Class

The general purpose of Loxapac is to help manage severe mental disturbances by stabilizing overactive nerve signaling in the brain. Loxapine achieves its function primarily by acting as a dopamine receptor antagonist, which regulates excessive dopamine activity. This action is proposed to be mediated through high-affinity antagonism of both dopamine D2 and serotonin 5-HT2A receptors. This means the medicine helps to rebalance key brain chemicals, which is the cornerstone of its utility in addressing generalized psychosis and acute agitation.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Loxapac?

Possible Side Effects and Safety Information

The safety profile of Loxapac (Loxapine) is defined by officially documented adverse reactions classified by frequency and body system, as established in regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Key Safety Classifications

Serious Adverse Reactions The official labeling includes specific, critical safety information. All conventional antipsychotic agents, including Loxapine, carry a Black Box Warning for increased mortality in elderly patients with dementia-related psychosis. Other serious adverse reactions documented include Neuroleptic Malignant Syndrome (NMS), a potentially fatal complex, and the risk of developing Tardive Dyskinesia (TD), particularly with prolonged use. The potential for seizures and blood disorders such as agranulocytosis is also documented.

Common Adverse Reactions Adverse effects officially classified as Very Common or Common include those related to the central nervous system and anticholinergic activity. These may involve drowsiness or sedation, dry mouth, constipation, dizziness, and Extrapyramidal Symptoms (EPS) such as muscle stiffness or restlessness. These effects are often noted as being more frequent during the initial phase of therapy.

Classification Examples of Reactions
Very Common Sedation, Dry mouth, Constipation
Common Dizziness, Headache, Extrapyramidal Symptoms

Population-Specific Safety

Safety constraints are defined for specific groups. The medicine is formally contraindicated in elderly patients with dementia-related psychosis. Furthermore, the official label notes that newborns exposed during the third trimester of pregnancy have been reported to exhibit extrapyramidal and/or withdrawal symptoms following birth. Caution is also advised in patients with a history of convulsive disorders or cardiovascular disease.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Loxapac (Loxapine) may lead to severe systemic toxicity, necessitating immediate emergency attention. Official regulatory documents indicate that overdosage often presents as profound central nervous system depression, including somnolence, loss of consciousness, and the potential for coma.

Documented Overdose Manifestations

The officially documented clinical signs of overdosage include convulsive seizures, pronounced extrapyramidal symptoms (uncontrollable movements), respiratory depression (slowed breathing), and bradycardia (slowed heartbeat). Furthermore, severe cardiovascular instability may occur, specifically profound hypotension (dangerously low blood pressure) and cardiac dysrhythmias. Regulatory reviews have noted the risk of respiratory arrest as a severe, life-threatening outcome.

Emergency Response and Management

Immediate medical help must be sought if the affected individual has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. Regulatory authorities mandate that you call emergency services immediately or contact a Poison Control Helpline. There is no specific antidote known for Loxapine. Treatment is strictly symptomatic and supportive and requires careful medical monitoring, including continuous ECG monitoring. When treating severe hypotension, specific agents like norepinephrine or phenylephrine are preferred; the use of epinephrine should be avoided as it may exacerbate low blood pressure.

Therapeutic Uses of Loxapac

What Loxapac Treats: Main Uses and Benefits

Loxapac (Loxapine) is commonly used to help manage significant psychiatric conditions, providing supportive relief in managing both long-term illness and acute behavioral crises. The therapeutic benefit is applied across distinct symptomatic domains. Loxapine is indicated for the management of schizophrenia, supporting symptomatic relief for severe manifestations of the illness.


Loxapac is commonly used in the management and maintenance of Schizophrenia and other Psychotic Disorders. It is applied across domains where additional symptomatic support is needed, specifically targeting pronounced manifestations that create noticeable functional strain. This domain helps address positive psychotic symptoms, such as disturbing hallucinations and persistent delusions, as well as general thought disorganization.

The medication is also highly relevant in clinical settings marked by temporary physiological imbalance, specifically for episodes involving severe psychomotor agitation. It is used during phases when symptoms become temporarily overwhelming, such as overwhelming restlessness or potentially aggressive behavior. The benefit here supports a calming effect in acute, unstable symptom patterns, which assists with stabilization during clinical assessment.

“This supportive therapeutic action contributes to improved comfort during symptomatic periods and and may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Severe Psychomotor Agitation


Loxapac is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive in conditions presenting with acute episodes and recurrent manifestations. It offers symptomatic relief that helps patients cope more steadily with difficult episodes, supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Loxapac (Loxapine) eligibility is strictly defined by regulatory labeling. Use is generally established for adults (18 years and older) for approved indications.

Populations Who Cannot Use the Medicine (Contraindications)

Loxapac is contraindicated and must not be used in several groups. These include individuals with a known hypersensitivity to loxapine and patients in comatose states or severe drug-induced depressed states (e.g., alcohol, narcotics). Critically, Loxapac is not approved and is contraindicated for use in elderly patients with dementia-related psychosis due to an associated increased risk of death.

For the inhaled formulation, the medication is contraindicated for those with a history of asthma, COPD, or other lung diseases associated with bronchospasm.

Age and Physiological Restrictions

For pediatric patients (under 18 years), use is not recommended as safety and efficacy have not been established. Older adults generally require closer monitoring. Use during pregnancy and lactation is generally not recommended because safe use has not been established; exposure during the third trimester may pose specific risks to the neonate.

Specific caution is also required for populations with a history of seizure disorders or certain cardiovascular conditions, as defined in the official prescribing information.

What should I know about interactions with other medicines?

Loxapac's interaction profile is officially defined by specific pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Documented Pharmacodynamic Interactions

Co-administration with other CNS Depressants (including Alcohol, barbiturates, general anesthetics, opiate analgesics, and sedative/hypnotics) may result in additive CNS depressant effects, which is a high-level pharmacodynamic interaction that imposes restrictions on combined use. Loxapine is formally contraindicated in patients with severely drug-induced depressed states caused by these substances. Co-administration with Anticholinergic Drugs may lead to documented potentiated anticholinergic effects. Furthermore, the combination of Loxapine with Lithium has been occasionally associated with an acute encephalopathic syndrome.

Exposure-Modifying and Metabolic Interactions

Certain Anticonvulsants (such as Carbamazepine, Phenobarbital, and Phenytoin) may officially decrease plasma Loxapine concentrations due to their effect on drug metabolism. Conversely, regulatory documents state that Loxapine may also decrease serum Phenytoin concentrations. Strong CYP1A2 inhibitors (e.g., Fluvoxamine, Ciprofloxacin) should be avoided when possible, as they can alter Loxapine's exposure profile.

Procedural and Formulation-Specific Restrictions

The official labels document procedural constraints for treating Loxapine-induced hypotension: the use of Epinephrine or Dopamine is not recommended because Loxapine formally inhibits their vasopressor effect. The inhalation powder formulation carries a distinct, formal contraindication for patients who are currently using medications to treat airways diseases (such as asthma or COPD).

Mechanism of Action

Loxapine functions primarily as a non-selective receptor antagonist within the central nervous system. Its principal biological targets are G protein-coupled receptors (GPCRs) for both dopamine and serotonin neurotransmitter systems, specifically demonstrating high-affinity antagonism at postsynaptic dopamine D2 receptors ( D2) and serotonin 5-hydroxytryptamine 2 A receptors ( 5-HT2 A).

Antagonism of these receptors blocks the binding of their endogenous ligands, inhibiting the normal downstream signaling cascades. D2 receptor blockade halts the decrease in cyclic adenosine monophosphate (cAMP) synthesis that is typically mediated by the G i/ o protein pathway. 5-HT2 A receptor antagonism prevents the activation of the phospholipase C (PLC)-mediated cascade, which ordinarily leads to the production of inositol triphosphate ( IP3) and diacylglycerol (DAG).

Loxapine also acts as an antagonist at several other receptors, including D4 dopamine, 5 -HT2 C serotonin, alpha1-adrenergic, histamine H1, and muscarinic cholinergic M1 receptors, contributing to its overall pharmacodynamic profile. The systemic consequence of these multiple antagonisms is a broad modulation of neurotransmission across various neuronal pathways.

Dosage and Administration Information

How Loxapac is Used: Official Administration Guidelines

Loxapac (Loxapine) is administered through distinct routes, each with specific procedural requirements. The medication is available as capsules and an oral concentrate for long-term use, and as a solution for injection (IM) or powder for oral inhalation for acute use.


Administration Scope

Feature Official Use Instructions
Routes Oral, Intramuscular (IM), and Inhalation.
Dosing Pattern Oral: Dosage typically starts at 20 mg daily and is titrated over 7 to 10 days toward the usual maintenance range of 60 mg to 100 mg daily. The maximum daily dosage is 250 mg.
Inhalation: Reserved for acute use, with a single dose of 9.1 mg or 10 mg. Some protocols permit a single repeat dose after 2 hours, strictly limiting total administration per 24 hours.
Frequency Oral doses are administered in divided doses multiple times a day. IM and inhaled doses are for single or short-term, as-needed (PRN) use.
Special Conditions Oral capsules may be taken with or without food. The oral concentrate must be mixed with liquid, such as orange or grapefruit juice, before ingestion.

Procedural and Population Rules

The inhaled form requires administration by a healthcare professional in a specific medical setting, and the patient must be observed for one hour after receiving the dose. For oral therapy, if a dose is missed, individuals should skip the missed dose if it is almost time for the next scheduled dose; doubling the dose is not permitted. The safety and efficacy of Loxapine have not been established for use in pediatric patients.

Recent Clinical Evidence

Research evidence / Overview of studies for Loxapac

Evidence for Management of Schizophrenia

Research exploring Loxapac in studies related to schizophrenia includes short-term Randomized Controlled Trials (RCTs) and subsequent syntheses of that data through systematic reviews. This body of evidence primarily focused on adult patients in studies examining chronic and acute symptom patterns of schizophrenia. Researchers used these studies to explore how symptoms change over time, specifically monitoring outcomes related to general mental state and assessment scales. Standardized rating scales were used in this research to measure symptom intensity or variability.

In these studies, Loxapine was evaluated in comparison to a placebo (an inactive substance) and comparisons were made against placebo and with other first-generation antipsychotic medications. The research describes shifts measured during the study period, with findings describing patterns observed in the symptoms of the study populations over the short durations of the trials. The evidence contributes to the understanding of symptom patterns, particularly focusing on how symptoms were measured in the observed populations over observation periods that typically lasted only a few weeks.

Comparing Loxapine in Clinical Trials

Studies monitored Loxapine for whether symptom scores for hallucinations and delusions shifted, which were measured using specialized assessment scales. Research also described patterns related to how symptom scores shifted when Loxapac was observed against other commonly used medications in this class. Findings describe group patterns, not personal outcomes, and reflect the specific conditions under which these short-term studies were conducted.

Evidence for Acute Treatment of Severe Psychomotor Agitation

Evidence for the study of Loxapac in research scenarios involving severe psychomotor agitation, stems from Randomized, Double-Blind, Placebo-Controlled Trials. These studies involved adult patients where symptoms had become more noticeable, often associated with schizophrenia or bipolar disorder. This research specifically examined the short-term symptom changes associated with the rapid-acting formulations of Loxapine. Studies monitored outcomes describing episodic or acute changes, focusing on the speed and degree to which agitation scores shifted.

Focus on Onset and Duration of Acute Effect

Studies exploring short-term symptom changes focused on outcomes related to episodic or acute changes, using specific time-points, such as ten minutes or two hours post-administration, to describe the onset of observed change. Research examined the duration of this initial measured change to understand patterns of stability shortly after the acute phase. Findings describe patterns observed in agitation scores in the Loxapine administration group when compared to the placebo group in these controlled, short-term research settings.

What Is Still Uncertain About Loxapac Research

The primary efficacy research is supported by studies that assessed short-term outcomes, but formal, large-scale clinical trials designed to track patient outcomes over periods exceeding several months are limited. Long-term effects are not fully established, and comparative evidence is lacking, particularly regarding how Loxapine was observed against many of the second-generation antipsychotics in contemporary, large-scale RCTs. Data for groups such as older adults with dementia-related psychosis or pediatric populations are limited, meaning research is limited regarding outcomes in these specific groups.

Key Studies & References

  1. A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia

Frequently Asked Questions (FAQ)

Common questions about Loxapac (FAQ)

Q: Is Loxapac considered an antidepressant?

Loxapac is officially classified as a first-generation antipsychotic, which helps manage severe mental disturbances. However, regulatory-cited information notes that one of the primary active metabolites of loxapine is amoxapine, which is itself recognized as a tricyclic antidepressant.


Q: Does Loxapac cause weight gain?

While significant weight gain may not be listed among the most common adverse reactions in all official documents, some prescribing information recommends monitoring body weight before and during treatment. This monitoring is documented in prescribing information.


Q: Can Loxapac affect sleep patterns?

Official documents describe effects that can impact sleep. Documented common side effects of Loxapac include drowsiness or sedation, which is very common. Conversely, some reports also list difficulty sleeping as a possible adverse reaction.


Q: Can Loxapac be taken if a person has heart problems?

Official documentation indicates that Loxapac is contraindicated for use in patients with a severe heart or blood vessel disorder. Caution is also generally advised for patients with a history of cardiovascular disease.


Q: Are there any specific liver or kidney conditions that prevent Loxapac use?

Official documentation states Loxapac is contraindicated (should not be used) in patients with a diagnosis of severe kidney problems or liver disease.


Q: Does Loxapac affect blood sugar levels?

Official documents list increased blood sugar as a potential side effect. Regulatory guidelines may advise that a patient's blood sugar levels be routinely monitored during treatment.


Q: What happens if Loxapac is stopped suddenly?

Official information indicates that a gradual reduction of Loxapac is often advised prior to stopping completely. This is done to help the body adjust and may prevent the original condition from potentially worsening.


Q: Does Loxapac interact with birth control pills?

Regulatory documents note that the use of oral contraceptives (commonly referred to as 'The Pill') is listed as a potential risk factor for developing blood clots in individuals taking Loxapac.


Q: Are there official reports about the potential for abuse or dependence with Loxapac?

Loxapac is officially classified as a prescription-only medication and is not listed as a federally controlled substance, which is the regulatory classification for drugs considered to have a high risk of abuse or dependence.


Q: Why do doctors prescribe Loxapac for short-term versus long-term use?

Official documentation distinguishes the oral formulation for chronic, ongoing management from the inhalation or IM (injection) formulations for the acute treatment of agitation. This difference is primarily due to the latter's design to achieve rapid delivery and a quick onset of effect for immediate issues.


Q: Does Loxapac help with mood stabilization?

Loxapac is officially approved for the treatment of schizophrenia and for the acute treatment of agitation associated with schizophrenia or bipolar I disorder. The inclusion of bipolar I disorder is an indirect link to managing severe mood-related disturbance.


Q: Is Loxapine known by any other brand names internationally?

Yes, the active ingredient loxapine is also marketed under other brand names internationally. These include Loxitane and Adasuve (which is the brand name for the specialized inhalation powder formulation).


Q: Does Loxapac have known interactions with herbal supplements?

Official consumer information for Loxapac advises individuals to inform their healthcare provider about the use of herbal products or supplements, as potential interactions may exist.


Q: What is the maximum amount of time Loxapac is typically used for?

Regulatory-cited research mainly covers short-term outcomes, typically up to several weeks of treatment. Formal, large-scale clinical trials designed to track patient outcomes over periods exceeding several months are limited, meaning long-term effects are not fully established in controlled research.


Q: How long does Loxapac stay in your system?

Information derived from studies on how the body breaks down the medication is available. The time it takes for the concentration of Loxapac in the body to be reduced by half (known as the elimination half-life) has been reported to be approximately 7 hours.


Q: How quickly can someone expect Loxapac to start working? (Chronic Oral Use)

For chronic oral use, the dosage is typically adjusted over the first 7 to 10 days until symptoms are effectively managed. This titration period is the process used to achieve the optimal therapeutic dose.


Q: What is the generally described time frame for feeling the full effects of Loxapac?

The full effects are typically seen once the daily dose is within the usual therapeutic and maintenance range, which is generally achieved through dose adjustment over the first 7 to 10 days of treatment.


Q: Does Loxapac interact with common over-the-counter pain relievers?

Regulatory documents caution against co-administration with other CNS depressants (which includes certain over-the-counter cold, allergy, or sleep aids) due to the risk of increased sedation. A specific interaction is noted for combinations containing acetaminophen and phenyltoloxamine.


Q: What kind of monitoring is typically required while taking Loxapac?

Routine monitoring is often required to track a patient’s progress and identify potential adverse effects. This includes checks on body weight, blood sugar levels, and the number of white blood cells. Patients are also monitored for signs of movement disorders like Tardive Dyskinesia.


Q: What are the contraindications listed for Loxapac?

Official contraindications include known hypersensitivity to the drug and use in patients in comatose states or severe drug-induced depressed states. It is also contraindicated in elderly patients with dementia-related psychosis. Furthermore, the inhaled form has contraindications for pre-existing pulmonary diseases like asthma or COPD.

How should Loxapac be stored and disposed of?

Storage Conditions and Handling

The official regulatory storage profile for Loxapac (Loxapine) capsules mandates keeping the medication at room temperature. To maintain product stability, it must be protected from excess heat and moisture; therefore, storage in high-humidity areas, such as a bathroom, is prohibited.

Packaging and Child Safety

The product must remain in its original container, which must be kept tightly closed. The safety instruction is non-negotiable: the medication must be stored out of the sight and reach of children, typically in a locked or secure location that is up and away.

Disposal Requirements

Unused or expired Loxapac must be discarded according to official procedures, such as those provided by the FDA. The preferred method is a local drug take-back program. Medicines should not be flushed down the toilet or poured down the sink. If a take-back option is unavailable, the product should be mixed with an unappealing substance, sealed in a bag, and then placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loxapac found in:

A-Z Index: